Lymphoma: all 5,623 studies

Page 12 of 57. Open to participants first (823), then studies with results posted, then the rest; newest registration first within each.

• Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)TerminatedNCT02951156Phase 3Results posted
• Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)CompletedNCT02939014Phase 2Results posted
• BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or LeukaemiaCompletedNCT02933320Phase 1/2Results posted
• TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular LymphomaCompletedNCT02927964Phase 1/2Results posted
• A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal TypeCompletedNCT02927925Phase 2Results posted
• Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02926833Phase 1/2Results posted
• A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin LymphomaCompletedNCT02919670Not applicableResults posted
• Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHLCompletedNCT02910063Phase 2/3Results posted
• tTF-NGR Phase I StudyCompletedNCT02902237Phase 1Results posted
• Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell LymphomaTerminatedNCT02898259Phase 1/2Results posted
• Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant PatientsTerminatedNCT02877082Phase 2Results posted
• A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's LymphomasTerminatedNCT02875223Phase 1Results posted
• Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin LymphomaTerminatedNCT02875067Phase 1/2Results posted
• TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02874404Phase 2Results posted
• Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular LymphomaCompletedNCT02871219Phase 2Results posted
• Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell TransplantCompletedNCT02869633Phase 2Results posted
• Carfilzomib and TGR-1202 in Treatment of R/R LymphomaTerminatedNCT02867618Phase 1/2Results posted
• A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)CompletedNCT02857426Phase 2Results posted
• Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular LymphomaTerminatedNCT02855359Phase 2Results posted
• Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone LymphomaCompletedNCT02853370Phase 2Results posted
• Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT02824029Phase 2Results posted
• Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion LymphomaTerminatedNCT02823327Results posted
• Expectations and Priorities of Elderly Patients for a First Medical Treatment for CancerCompletedNCT02821793Results posted
• DA-EPOCH-Rituximab/Metformin (RM) for Double Hit LymphomaTerminatedNCT02815397Phase 2Results posted
• A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin LymphomaTerminatedNCT02811679Phase 2Results posted
• A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular LymphomaCompletedNCT02809053Phase 3Results posted
• Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLLTerminatedNCT02784834Phase 1Results posted
• An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's LymphomaCompletedNCT02783300Phase 1Results posted
• Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid TumorsCompletedNCT02780804Phase 1Results posted
• BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic LymphomaTerminatedNCT02763384Phase 2Results posted
• Cellular Immunotherapy for Viral Induced Cancer - EBV Positive LymphomasTerminatedNCT02763254Phase 2Results posted
• A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02760485Phase 1/2Results posted
• Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02744612Phase 2Results posted
• Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell LymphomaCompletedNCT02736617Phase 2Results posted
• A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT02733042Phase 1/2Results posted
• Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDSCompletedNCT02730299Phase 3Results posted
• A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02729896Phase 1/2Results posted
• Phase II Study of TAK228 in Relapsed LymphomaTerminatedNCT02727777Phase 1/2Results posted
• Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) StudyTerminatedNCT02717949Phase 4Results posted
• Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesTerminatedNCT02711137Phase 1/2Results posted
• JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT02706405Phase 1Results posted
• A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin LymphomaTerminatedNCT02703272Phase 3Results posted
• Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCTCompletedNCT02692248Phase 2Results posted
• Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)CompletedNCT02689453Phase 1Results posted
• Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant RecurrenceTerminatedNCT02681302Phase 1/2Results posted
• Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell LymphomaCompletedNCT02676778Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC AlterationsCompletedNCT02674750Phase 2Results posted
• Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)CompletedNCT02669017Phase 1Results posted
• Administration of T Lymphocytes for Prevention of Relapse of LymphomasActive, not recruitingNCT02663297Phase 1Results posted
• Study of FF-10502-01 in Patients With Advanced Solid Tumors and LymphomasCompletedNCT02661542Phase 1/2Results posted
• T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell MalignanciesCompletedNCT02659943Phase 1Results posted
• Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)CompletedNCT02658968Phase 1Results posted
• A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)CompletedNCT02653976Phase 2Results posted
• TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed LymphomaCompletedNCT02652468Not applicableResults posted
• Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory LymphomasCompletedNCT02650999Phase 1/2Results posted
• Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesCompletedNCT02639559Phase 2Results posted
• Smart Start: A Phase II Study of Rituximab, Lenalidomide, and IbrutinibCompletedNCT02636322Phase 2Results posted
• Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell LymphomaCompletedNCT02633137Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac DiseaseCompletedNCT02633020Phase 2Results posted
• Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/LymphomaCompletedNCT02631746Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaCompletedNCT02631577Phase 1/2Results posted
• R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT02628405Phase 1/2Results posted
• Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)TerminatedNCT02626455Phase 3Results posted
• A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) ParticipantsTerminatedNCT02624986Phase 1/2Results posted
• To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCLCompletedNCT02624492Phase 2Results posted
• Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)TerminatedNCT02624388Phase 2Results posted
• MabionCD20 Compared to MabThera in Lymphoma PatientsCompletedNCT02617485Phase 3Results posted
• A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02611323Phase 1/2Results posted
• Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)TerminatedNCT02603419Phase 1Results posted
• A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02600897Phase 1/2Results posted
• A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02596971Phase 1/2Results posted
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerCompletedNCT02595866Phase 1Results posted
• A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's LymphomaCompletedNCT02594384Phase 1Results posted
• Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell LymphomaTerminatedNCT02594163Phase 2Results posted
• Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD ProphylaxisCompletedNCT02593123Phase 2Results posted
• Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell LymphomaTerminatedNCT02592876Phase 2Results posted
• Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC SubtypeTerminatedNCT02589145Phase 1/2Results posted
• A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)CompletedNCT02588651Phase 2Results posted
• Reduced Intensity Conditioning Transplant Using Haploidentical DonorsCompletedNCT02581007Phase 2Results posted
• A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.CompletedNCT02578316Phase 1Results posted
• Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)CompletedNCT02576990Phase 2Results posted
• Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCLTerminatedNCT02572453Phase 2Results posted
• A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin LymphomaCompletedNCT02572167Phase 1/2Results posted
• A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular LymphomaCompletedNCT02569996Phase 3Results posted
• Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)TerminatedNCT02568683Phase 1/2Results posted
• Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell LymphomaCompletedNCT02567656Phase 1Results posted
• Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02566304Phase 2Results posted
• Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHLCompletedNCT02564744Phase 2Results posted
• Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's LymphomaCompletedNCT02561273Phase 1/2Results posted
• Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular LymphomaCompletedNCT02541565Phase 1Results posted
• Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma ParticipantsCompletedNCT02536664Results posted
• Dose Optimization Study of Idelalisib in Follicular LymphomaTerminatedNCT02536300Phase 3Results posted
• Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young AdultsTerminatedNCT02535806Phase 2Results posted
• Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin LymphomaTerminatedNCT02535247Phase 1/2Results posted
• Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone LymphomaCompletedNCT02532257Phase 2Results posted
• Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)TerminatedNCT02531308Phase 2Results posted
• Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First RemissionTerminatedNCT02530125Phase 2Results posted
• A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell LymphomaCompletedNCT02529852Phase 1/2Results posted
• Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or LymphomaTerminatedNCT02518750Phase 2Results posted
• A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)TerminatedNCT02509039Phase 1Results posted

← Lymphoma overview